All News
Filter News
Found 808,606 articles
-
VivaVision Biotech Announces Positive Topline Results of VVN001 in the Phase 2 Clinical Study for the Treatment of Dry Eye Disease
3/22/2022
VivaVision Biotech, Inc. (VivaVision), an ophthalmic pharmaceutical developer focusing on discovery and development of innovative therapies for ocular diseases, today announced positive topline results from a Phase 2 clinical study of VVN001 in patients with dry eye disease.
-
Matinas BioPharma to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
3/22/2022
Matinas BioPharma announced that Jerry Jabbour, Chief Executive Officer, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest.
-
Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results
3/22/2022
Exagen Inc. today reported financial results for the fourth quarter and full year ended December 31, 2021.
-
Ensartinib Secured Its First Approval for 1st Line Treatment in ALK+ NSCLC
3/22/2022
Xcovery Holdings, Inc., an oncology focused bio-pharmaceutical company, today announced that Xcovery’s affiliate Betta Pharmaceuticals has received the National Medical Products Administration (NMPA)’s approval of ensartinib in China for the first-line treatment of ALK-positive non-small cell lung cancer (NSCLC).
-
Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer
3/22/2022
Aravive, Inc., a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced the appointment of industry veteran, Scott Dove, Ph.D., as Chief Operating Officer.
-
POINT Biopharma Confirms No Delays to SPLASH Trial Due to Recent Global Lutetium Supply Interruption
3/22/2022
POINT Biopharma Global Inc. today affirmed that a recent reactor shutdown in Europe and current geopolitical events concerning Russia and Ukraine have not impacted the Company’s trial timelines or the Company’s 2022 business outlook.
-
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences - Mar 22, 2022
3/22/2022
Avadel Pharmaceuticals plc, a company focused on transforming medicines to transform lives, announced that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming investor conferences:
-
Arch Grants, BioGenerator, Donald Danforth Plant Science Center, and The Yield Lab Partner to create an AgriFoodTech Arch Grants Funding Track
3/22/2022
Each year, Arch Grants funds 20-25 early-stage companies through its annual Startup Competition.
-
Sepha’s new EZ Blister+ enables 21 CFR Part 11 compliant micro-batches
3/22/2022
Sepha, the Northern Ireland-based manufacturer of pharmaceutical packaging and equipment, has developed a new compact small-batch blister packaging machine with full traceability and electronic data storage capabilities.
-
NEW INDEPENDENT MARKET RESEARCH SAYS 84% OF US HEALTHCARE PROFESSIONALS LIKELY TO USE ORVIGLANCE IMAGING AGENT IN TARGET POPULATION
3/22/2022
The independently conducted survey asked 270 healthcare professionals in the US (radiologists, oncologists and nephrologists) about their choices of imaging and contrast agents in patients with cancer.
-
Home DNA Test Kit Market USD 10 Billion Opportunity By 2028
3/22/2022
Global DNA Test Kit Market Opportunity > USD 10 Billion by 2028.
-
Biomarkers In Breast Cancer Drug Development
3/22/2022
Breast cancer is the leading type of cancer in terms of number of cases and rapid increase in the number of newly diagnosed breast cancer is observed during the past few years.
-
Proscia and Visiopharm Partner to Deliver AI-Powered Pathology to Drive Insight in Cancer Diagnosis
3/22/2022
Proscia®, a leader in digital and computational pathology solutions, and Visiopharm, a world leader in AI-driven precision pathology software, today announced a strategic partnership to deliver integrated AI-enabled solutions that aim to improve clinical decision making for cancer care.
-
Paige Launches AI Software to Enable Accurate and Efficient Detection of Breast Cancer Metastases in Lymph Nodes
3/22/2022
Paige, the global leader in AI-based diagnostic software in pathology, today launched its latest product, Paige Breast Lymph Node, an AI medical device software that helps pathologists detect if breast cancer has metastasized to lymph nodes, concurrent with pathologists’ own interpretive review*.
-
Augmented Reality Medical Technology Company ImmersiveTouch Announces Strategic Collaboration with Mayo Clinic
3/22/2022
ImmersiveTouch, the leading medical technology company with proprietary image-guided virtual and augmented reality (VR/AR) surgical planning & navigation platforms, today announced a strategic collaboration with Mayo Clinic.
-
Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases
3/22/2022
Akron BioProducts, a leading manufacturer of cGMP-compliant technologies for cell and gene therapy, and Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced an agreement to develop and manufacture cGMP nucleases.
-
Study Finds Cementless Knee Replacement Outcomes Comparable to Standard Knee Implant, Less Time Needed in OR
3/22/2022
Cementless knee replacement, an alternative approach to traditional cemented knee replacement surgery, is garnering interest in the field of orthopedic surgery.
-
Artio Medical Receives FDA Clearance for Solus Gold™ Embolization Device
3/22/2022
Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, today announced it received US Food and Drug Administration (FDA) clearance for its Solus Gold Embolization Device, a next-generation product for peripheral vascular occlusion.
-
Urovant Sciences Announces Publication of New Review of Efficacy and Safety Data for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients in the Journal Therapeutics and Clinical Risk Management
3/22/2022
Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced the publication of a new review of data on GEMTESA (vibegron) 75 mg in the peer-reviewed journal, Therapeutics and Clinical Risk Management (https://bit.ly/Vibegron).
-
Exactech Announces New Patent, Strengthening Company’s Position in Joint Replacement Soft Tissue Management
3/22/2022
Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent #11,278,338 for the Newton™ Knee.